<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Alzheimers Res Ther</journal-id><journal-id journal-id-type="iso-abbrev">Alzheimers Res Ther</journal-id><journal-title-group><journal-title>Alzheimer's Research &#x00026; Therapy</journal-title></journal-title-group><issn pub-type="epub">1758-9193</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26948580</article-id><article-id pub-id-type="pmc">4780148</article-id><article-id pub-id-type="publisher-id">178</article-id><article-id pub-id-type="doi">10.1186/s13195-016-0178-x</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>A single dose of the &#x003b3;-secretase inhibitor semagacestat alters the cerebrospinal fluid peptidome in humans</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>H&#x000f6;ltt&#x000e4;</surname><given-names>Mikko</given-names></name><address><email>mikko_holtta@hotmail.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Dean</surname><given-names>Robert A.</given-names></name><address><email>dean_robert_a@lilly.com</email></address><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Siemers</surname><given-names>Eric</given-names></name><address><email>siemers_eric_r@lilly.com</email></address><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Mawuenyega</surname><given-names>Kwasi G.</given-names></name><address><email>mawuenyegak@neuro.wustl.edu</email></address><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name><surname>Sigurdson</surname><given-names>Wendy</given-names></name><address><email>sigurdsonw@neuro.wustl.edu</email></address><xref ref-type="aff" rid="Aff3"/><xref ref-type="aff" rid="Aff4"/></contrib><contrib contrib-type="author"><name><surname>May</surname><given-names>Patrick C.</given-names></name><address><email>may_patrick_c@lilly.com</email></address><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Holtzman</surname><given-names>David M.</given-names></name><address><email>holtzman@neuro.wustl.eduqaw</email></address><xref ref-type="aff" rid="Aff3"/><xref ref-type="aff" rid="Aff4"/><xref ref-type="aff" rid="Aff5"/></contrib><contrib contrib-type="author"><name><surname>Portelius</surname><given-names>Erik</given-names></name><address><email>erik.portelius@neuro.gu.se</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Zetterberg</surname><given-names>Henrik</given-names></name><address><email>henrik.zetterberg@clinchem.gu.se</email></address><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff6"/></contrib><contrib contrib-type="author"><name><surname>Bateman</surname><given-names>Randall J.</given-names></name><address><email>batemanr@neuro.wustl.edu</email></address><xref ref-type="aff" rid="Aff3"/><xref ref-type="aff" rid="Aff4"/><xref ref-type="aff" rid="Aff5"/></contrib><contrib contrib-type="author"><name><surname>Blennow</surname><given-names>Kaj</given-names></name><address><email>kaj.blennow@neuro.gu.se</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-6193-6193</contrib-id><name><surname>Gobom</surname><given-names>Johan</given-names></name><address><phone>+46 (0)31 3432377</phone><email>johan.gobom@neuro.gu.se</email></address><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1"><label/> Department of Psychiatry and Neurochemistry, Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, SU/M&#x000f6;lndal Hospital, 431 80 M&#x000f6;lndal, Sweden </aff><aff id="Aff2"><label/>Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Headquarters, Indianapolis, IN 46285 USA </aff><aff id="Aff3"><label/>Department of Neurology, Washington University School of Medicine, 660 South Euclid, Campus Box 8111, St. Louis, MO 63110 USA </aff><aff id="Aff4"><label/>Alzheimer&#x02019;s Disease Research Center, Washington University School of Medicine, 660 South Euclid, Campus Box 8111, St. Louis, MO 63110 USA </aff><aff id="Aff5"><label/>Hope Center for Neurological Disorders, Washington University School of Medicine, 660 South Euclid, Campus Box 8111, St. Louis, MO 63110 USA </aff><aff id="Aff6"><label/>UCL Institute of Neurology, Queen Square, London, WC1N 3BG UK </aff></contrib-group><pub-date pub-type="epub"><day>7</day><month>3</month><year>2016</year></pub-date><pub-date pub-type="pmc-release"><day>7</day><month>3</month><year>2016</year></pub-date><pub-date pub-type="collection"><year>2016</year></pub-date><volume>8</volume><elocation-id>11</elocation-id><history><date date-type="received"><day>22</day><month>12</month><year>2015</year></date><date date-type="accepted"><day>29</day><month>1</month><year>2016</year></date></history><permissions><copyright-statement>&#x000a9; H&#x000f6;ltt&#x000e4; et al. 2016</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>In Alzheimer&#x02019;s disease, beta-amyloid peptides in the brain aggregate into toxic oligomers and plaques, a process which is associated with neuronal degeneration, memory loss, and cognitive decline. One therapeutic strategy is to decrease the production of potentially toxic beta-amyloid species by the use of inhibitors or modulators of the enzymes that produce beta-amyloid from amyloid precursor protein&#x000a0;(APP). The failures of several such drug candidates by lack of effect or undesired side-effects underscore the importance to monitor the drug effects in the brain on a molecular level. Here we evaluate if peptidomic analysis in cerebrospinal fluid&#x000a0;(CSF) can be used for this purpose.</p></sec><sec><title>Methods</title><p>Fifteen human healthy volunteers, divided into three groups, received a single dose of placebo or either 140&#x000a0;mg or 280&#x000a0;mg of the &#x003b3;-secretase inhibitor semagacestat (LY450139). Endogenous peptides in CSF, sampled prior to administration of the drug and at six subsequent time points, were analyzed by liquid chromatography coupled to mass spectrometry, using isobaric labeling based on the tandem mass tag approach for relative quantification.</p></sec><sec><title>Results</title><p>Out of 302 reproducibly detected peptides, 11 were affected by the treatment. Among these, one was derived from APP and one from amyloid precursor-like protein 1. Nine peptides were derived from proteins that may not be &#x003b3;-secretase substrates <italic>per se</italic>, but that are regulated in a &#x003b3;-secretase-dependent manner.</p></sec><sec><title>Conclusions</title><p>These results indicate that a CSF peptidomic approach may be a valuable tool both to verify target engagement and to identify other pharmacodynamic effects of the drug. Data are available via ProteomeXchange with identifier PXD003075.</p></sec><sec><title>Trial registration</title><p><ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/results/NCT00765115">NCT00765115</ext-link>, registered 30/09/2008.</p></sec><sec><title>Electronic supplementary material</title><p>The online version of this article (doi:10.1186/s13195-016-0178-x) contains supplementary material, which is available to authorized users.</p></sec></abstract><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>CARS 1UL1 RR024992, NCRR 5P41 RR000954-32, NIDDK 2P60 DK020579-31, NIDDK SP30 DK056341-08</award-id><principal-award-recipient><name><surname>Bateman</surname><given-names>Randall J.</given-names></name></principal-award-recipient></award-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004359</institution-id><institution>Vetenskapsr&#x000e5;det</institution></institution-wrap></funding-source><award-id>521-2011-4709</award-id><principal-award-recipient><name><surname>Gobom</surname><given-names>Johan</given-names></name></principal-award-recipient></award-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004063</institution-id><institution>Knut och Alice Wallenbergs Stiftelse</institution></institution-wrap></funding-source></award-group><award-group><funding-source><institution>Emil och Wera Cornells stiftelse</institution></funding-source></award-group><award-group><funding-source><institution>Aina Wallstr&#x000f6;m och Mary-Ann Sj&#x000f6;bloms stiftelse</institution></funding-source></award-group><award-group><funding-source><institution>Demensf&#x000f6;rbundet</institution></funding-source></award-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100006285</institution-id><institution>Magnus Bergvalls Stiftelse (SE)</institution></institution-wrap></funding-source></award-group><award-group><funding-source><institution>Adlerbertska stiftelsen</institution></funding-source></award-group><award-group><funding-source><institution>Stiftelsen f&#x000f6;r Gamla Tj&#x000e4;narinnor</institution></funding-source></award-group><award-group><funding-source><institution>Gun och Bertil Stohnes stiftelse</institution></funding-source></award-group><award-group><funding-source><institution>Kungl och Hvitfeldtska stiftelsen</institution></funding-source></award-group><award-group><funding-source><institution>Wilhelm och Martina Lundgrens vetenskapsfond</institution></funding-source></award-group><award-group><funding-source><institution>The Torsten S&#x000f6;derberg Foundation at the Royal Swedish Academy of Sciences</institution></funding-source></award-group><award-group><funding-source><institution>Stiftelsen Greta Johansson och Brita Anderssons minnesfond</institution></funding-source></award-group><award-group><funding-source><institution>Eli Lilly investigator initiated research grant</institution></funding-source><award-id>H6L-MC-LFAM, NIA K23 AG030946</award-id><principal-award-recipient><name><surname>Bateman</surname><given-names>Randall J.</given-names></name></principal-award-recipient></award-group><award-group><funding-source><institution>The Knight Initiative for Alzheimer Research</institution></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2016</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Background</title><p>Alzheimer&#x02019;s disease (AD) is the most common form of dementia, affecting an increasing number of people worldwide and presenting a severe social and economic burden. A central aspect of the AD pathology is the formation of plaques in the brain, consisting of aggregated amyloid-&#x003b2; (A&#x003b2;) peptides [<xref ref-type="bibr" rid="CR1">1</xref>]. A variety of A&#x003b2; peptides are produced by enzymatic cleavage of the amyloid precursor protein (APP) by &#x003b2;-secretase (BACE) and &#x003b3;-secretase, of which the 42 amino acid long A&#x003b2; peptide (A&#x003b2;<sub>42</sub>) is most prone to aggregation [<xref ref-type="bibr" rid="CR2">2</xref>] and has been proposed to be the driving force in the disease [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. Several treatment strategies currently under investigation target the production or clearance of A&#x003b2;, e.g., immunotherapy with anti-A&#x003b2; antibodies, and treatment with &#x003b3;-secretase inhibitors (GSIs) and BACE inhibitors [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>]. While some of these strategies have yielded positive results in preclinical studies, they have so far been unsuccessful in slowing cognitive decline in human AD subjects [<xref ref-type="bibr" rid="CR7">7</xref>]. The GSI semagacestat showed promising effects in animal models [<xref ref-type="bibr" rid="CR8">8</xref>] and also decreased the amount of newly produced A&#x003b2; in humans [<xref ref-type="bibr" rid="CR9">9</xref>], but a phase III clinical trial failed to reach clinical endpoints and the drug turned out to have clinically significant adverse cognitive effects [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>].</p><p>Monitoring drug treatment effects on a molecular level is important to determine if a drug affects the intended target protein, but also to examine if other proteins are affected. The aim of this study was to test if an unbiased peptidomic approach can be used for this purpose. Previous studies have demonstrated the presence of a large number of endogenous peptides in cerebrospinal fluid (CSF) [<xref ref-type="bibr" rid="CR12">12</xref>&#x02013;<xref ref-type="bibr" rid="CR16">16</xref>]. While the majority of CSF proteomic studies to date follow the strategy of analyzing proteins digested with trypsin, endogenous peptides &#x02013; the CSF peptidome &#x02013; may also be a valuable source of biomarkers, particularly for studying biological events involving proteolytic processing. Recently, we reported on a method for multiplex quantitative peptidomic analysis in CSF, based on isobaric labeling using the tandem mass tag (TMT) approach [<xref ref-type="bibr" rid="CR17">17</xref>] combined with liquid chromatography-mass spectrometry (LC-MS) [<xref ref-type="bibr" rid="CR18">18</xref>].</p><p>In the current study we aim, by analyzing CSF from healthy subjects treated with the GSI semagacestat, to test if this approach can be used to detect drug treatment effects on proteolytic processing in the brain, to identify substrates affected by the drug and to quantify those effects. This is, to our knowledge, the first study that explores an endopeptidomic approach for the discovery of pharmacodynamic biomarkers in human CSF.</p></sec><sec id="Sec2" sec-type="materials|methods"><title>Methods</title><sec id="Sec3"><title>Experimental design and statistical rationale</title><p>CSF from a previous study was used, in which 20 healthy human volunteers received either placebo or 100&#x000a0;mg, 140&#x000a0;mg, or 280&#x000a0;mg semagacestat, and CSF was sampled every hour via an indwelling catheter in the lumbar thecal sac for 36&#x000a0;h following oral drug administration [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR19">19</xref>] (<ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT00765115">https://clinicaltrials.gov/ct2/show/NCT00765115</ext-link>). The study was approved by the Washington University Human Studies Committee, and was performed in compliance with the Helsinki Declaration. All participants and caregivers gave written informed consent. In the current study, CSF from the placebo group, the 140&#x000a0;mg group and the 280&#x000a0;mg group, sampled at 0&#x000a0;h, 3&#x000a0;h, 9&#x000a0;h, 12&#x000a0;h, 18&#x000a0;h, and 36&#x000a0;h were used (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). The time points were selected based on the results in previous studies [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR19">19</xref>], where a maximum A&#x003b2; inhibitory effect was seen between 9 and 12&#x000a0;h, and the values returned to approximately the same as for the placebo group at 36&#x000a0;h.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Distribution of the CSF samples within the TMT 6-plex sets</p></caption><table frame="hsides" rules="groups"><thead><tr><th>TMT label</th><th>126</th><th>127</th><th>128</th><th>129</th><th>130</th><th>131</th></tr></thead><tbody><tr><td>Time point</td><td>0&#x000a0;h</td><td>3&#x000a0;h</td><td>9&#x000a0;h</td><td>12&#x000a0;h</td><td>18&#x000a0;h</td><td>36&#x000a0;h</td></tr></tbody></table><table-wrap-foot><p>The CSF samples were labeled with TMT 6-plex reagents according to the table, and the ratios for the time points were calculated against the 0&#x000a0;h value. <italic>CSF</italic> cerebrospinal fluid, <italic>TMT</italic> tandem mass tag</p></table-wrap-foot></table-wrap></p><p>The experimental design is shown in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>. Neat CSF sampled at six consecutive time points before and after drug administration was labeled with isobaric TMT reagents, using a protocol recently developed in our laboratory [<xref ref-type="bibr" rid="CR18">18</xref>]. Briefly, 100&#x000a0;&#x003bc;l aliquots of neat CSF from each participant and time point was subjected to reduction and carbamidomethylation of cysteines followed by isobaric labelling using TMT 6-plex amino-reactive reagents (Thermo Scientific). The CSF sample corresponding to time point zero from each participant was labeled with TMT-126, the next time point from the same participant with TMT-127, and so on (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). The six samples from each participant were then combined into one TMT 6-plex set. The CSF samples from one participant were then combined into one TMT6-plex set. The TMT6-plex sets were subjected to ultrafiltration using 30&#x000a0;kDa molecular weight cut-off filters (Vivacon 2 HY, Sartorius Stedim). The flow-through, containing the endogenous peptide fraction, was desalted on C<sub>18</sub> cartridges (SEP-PAK, Waters), lyophilized and stored at -80&#x000a0;&#x000b0;C pending analysis. The CSF samples were analyzed by LC-MS in two technical replicates to improve the identification and quantification overlap between study participants.<fig id="Fig1"><label>Fig. 1</label><caption><p>Study design. CSF sampled at several time points following oral administration of semagacestat was subjected to labeling using TMT reagents 128-131. The combined labeled samples from each participant (TMT 6-plex set) were centrifuged through a 30&#x000a0;kDa molecular weight cut-off filter. The flow-through, containing the endogenous peptide fraction, was analyzed by LC-MS. The relative change in concentration of each identified peptide was calculated from the TMT reporter ion signals. <italic>CSF</italic> cerebrospinal fluid, <italic>TMT</italic> tandem mass tag, <italic>LC-MS</italic> liquid chromatography-mass spectrometry</p></caption><graphic xlink:href="13195_2016_178_Fig1_HTML" id="MO1"/></fig></p></sec><sec id="Sec4"><title>Liquid chromatography-mass spectrometry</title><p>Endogenous peptides were reconstituted in 12&#x000a0;&#x003bc;l of 2&#x000a0;% acetonitrile, 0.1&#x000a0;% trifluoroacetic acid. A sample of 6&#x000a0;&#x003bc;l was analyzed with nano-LC (Ultimate 3000, Thermo Scientific) with a C<sub>18</sub> trap column, and a C<sub>18</sub> separation column, coupled to a Q-Exactive electrospray ionization mass spectrometer (Thermo Scientific). The LC mobile phases were A: 0.05&#x000a0;% formic acid, and B: 84&#x000a0;% acetonitrile, 0.05&#x000a0;% formic acid. The samples were separated with a 160&#x000a0;minute gradient running from 3&#x000a0;% mobile phase B to 45&#x000a0;% mobile phase B. The mass spectrometer was operated in the positive ion mode. The instrument settings for the MS scans were: resolution 70,000; <italic>m/z</italic> range 400-1600; max injection time 250&#x000a0;ms; AGC target 1e6. Data-dependent acquisition was used to record up to 10 consecutive fragment ion spectra (MS2) per full scan spectrum, selecting precursor ions in decreasing order of intensity, and using 20&#x000a0;s dynamic exclusion, and charge state exclusion to exclude signals with unassigned charge, charge 1 and &#x0003e;5. The isolation window was set to 1.2&#x02009;<italic>m/z</italic>. The instrument settings for the MS2 scans were: resolution 35,000 for endogenous peptides and 17,500 for tryptic peptides; fixed first mass <italic>m/z</italic> 100; max injection time 120&#x000a0;ms for endogenous peptides and 60&#x000a0;ms for tryptic peptides; AGC target 1e5. Blank injections of mobile phase B were performed between the samples to avoid carry-over.</p></sec><sec id="Sec5"><title>Data analysis</title><p>The data from the two replicate runs of each participant were used in a MudPIT search using the software Proteome Discoverer 1.4 (Thermo Scientific). Protein identification was performed using Mascot v. 2.3 (Matrix Sciences, UK), searching the human subset of the UniProtKB/Swiss-Prot database (Release 2013-10, 88,266 sequences). The endogenous peptides were searched with the following settings: fixed modifications: TMT 6-plex modification of peptide N-termini and lysines, and carbamidomethylation of cysteines; variable modification: oxidation of methionine. The mass error tolerance was set to 10&#x000a0;ppm in MS mode and 20 milli-mass units in MS/MS mode. The peptide cut-off score for individual spectra was 10. A target false discovery rate value of 5&#x000a0;%, based on decoy database searches, was used as identification criterion. The quantification was done on the MS/MS level where reporter ions from the TMT 6-plex reagents were used for relative quantification. The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium [<xref ref-type="bibr" rid="CR20">20</xref>] via the PRIDE partner repository with the dataset identifier PXD003075 and 10.6019/PXD003075".</p><p>The CSF sample collected at time point 0&#x000a0;h was used as reference sample for each individual and the change in peptide abundance at later time points was calculated relative to the peptide&#x02019;s abundance at this time point.</p><p>A majority of the identified endogenous peptides increased between each time point regardless of whether the participant received placebo or the active substance. This has been observed for other analytes measured in these samples [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. The average increase over 24&#x000a0;h was 47&#x000a0;%. This drift was normalized toward baseline by subtracting the median ratio of the placebo group from the two groups that received the active substance for each peptide and time point.</p><p>The data were evaluated according to the following criteria: 1) the alterations of the peptide levels should be dose dependent; 2) the levels should not fluctuate substantially between each time point; 3) spikes at isolated time points were not considered to be drug dependent; 4) values from at least four individuals in each group were required to be present; and 5) the peptide levels should return toward the placebo groups&#x02019; values at 36&#x000a0;h. Because peptide abundances cannot be assumed to be normally distributed, the non-parametric Friedman test in the software PASW Statistics 18 (IBM) was used to evaluate the remaining peptides, employing a significance threshold of p&#x02009;&#x0003c;&#x02009;0.05.</p></sec></sec><sec id="Sec6" sec-type="results"><title>Results</title><p>The aim of the current study was to test if an unbiased endopeptidomic approach could be used to detect changes in the CSF endopeptidome in response to drug treatment. In total, 1798 endogenous peptides were identified and quantified in at least one TMT 6-plex set (corresponding to one individual). Of these, 302 endogenous peptides fulfilled the set quantification criteria of being identified and quantified in at least four participants in each of the three treatment groups (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S1). Of these, 11 peptides were significantly affected (p&#x02009;&#x0003c;&#x02009;0.05) by treatment with semagacestat (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>).<table-wrap id="Tab2"><label>Table 2</label><caption><p>Peptides affected by drug treatment</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Peptide</th><th rowspan="2">Protein</th><th colspan="2">p</th><th rowspan="2">Time at maximum decrease (h)</th><th rowspan="2">% maximum decrease</th></tr><tr><th>140&#x000a0;mg</th><th>280&#x000a0;mg</th></tr></thead><tbody><tr><td>EDVGSNK</td><td>Amyloid Precursor Protein and Amyloid beta A4 protein<sup>ab</sup>
</td><td>0.36</td><td char="." align="char">0.0035</td><td>9</td><td>42</td></tr><tr><td>DELAPAGTGVSREAVSG</td><td>Amyloid-like protein 1<sup>ab</sup>
</td><td>0.077</td><td char="." align="char">0.0018</td><td>12</td><td>32</td></tr><tr><td>SVQPDSPTDVNQENVPS</td><td>Tachykinin-3</td><td>0.065</td><td char="." align="char">0.0041</td><td>9</td><td>38</td></tr><tr><td>VTEDDEDEDDDKE</td><td>Testican-1</td><td>0.25</td><td char="." align="char">0.0039</td><td>18</td><td>26</td></tr><tr><td>AVTEDDEDE</td><td>Testican-1</td><td>0.065</td><td char="." align="char">0.0025</td><td>18</td><td>19</td></tr><tr><td>DDEDEDDDKE</td><td>Testican-1</td><td>0.41</td><td char="." align="char">0.0039</td><td>18</td><td>26</td></tr><tr><td>EKLPGQGVHSQGQGPGAN</td><td>Golgi apparatus protein 1<sup>a</sup>
</td><td>0.11</td><td char="." align="char">0.0020</td><td>18</td><td>20</td></tr><tr><td>DFLAEGGGVR</td><td>Fibrinogen alpha chain</td><td>0.66</td><td char="." align="char">0.0024</td><td>9</td><td>36</td></tr><tr><td>EPPPPPEPA</td><td>CD99 antigen-like protein 2<sup>a</sup>
</td><td>0.69</td><td char="." align="char">0.0041</td><td>18</td><td>24</td></tr><tr><td>TVVQPSVGAAAGPVVPPCPGRIRHFKV</td><td>Alpha-2-HS-glycoprotein</td><td>0.86</td><td char="." align="char">0.0039</td><td>9</td><td>27</td></tr><tr><td>DPNCSCATGGSCTCAGSCKCKE</td><td>Metallothionein-1E</td><td>-</td><td char="." align="char">0.0050</td><td>12</td><td>42</td></tr></tbody></table><table-wrap-foot><p>Endogenous CSF peptides that decreased in abundance after treatment with semagacestat</p><p>
<italic>CSF</italic> cerebrospinal fluid</p><p>
<sup>a</sup>transmembrane protein</p><p>
<sup>b</sup>previously reported gamma secretase substrate</p></table-wrap-foot></table-wrap></p><p>One of these was the peptide EDVGSNK, constituting fragment 22-28 of A&#x003b2; (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). Within the SwissProt sequence database, this peptide sequence is unique to APP. As the GSI blocks production of A&#x003b2; by inhibiting c-terminal cleavage from APP, decreased EDVGSNK indicates that the drug hits the target and affects A&#x003b2; production. The abundance of the peptide decreased by a maximum of 42&#x000a0;% after 9&#x000a0;h in the group that received 280&#x000a0;mg of semagacestat (p&#x02009;=&#x02009;0.0035) (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2b</xref>). A 13&#x000a0;% decrease was observed in the group that received 140&#x000a0;mg.<fig id="Fig2"><label>Fig. 2</label><caption><p>&#x003b2;-amyloid 22-28. The peptide EDVGSNK, constituting fragment 22-28 of &#x003b2;-amyloid within APP. <bold>a</bold> annotated MS2 spectrum. <bold>b</bold> Relative abundance of the peptide after semagacestat treatment. In the 280&#x000a0;mg dosage group the concentration of the peptide decreased to a minimum of 42&#x000a0;% at 9&#x000a0;h (p&#x02009;=&#x02009;0.0035), while in the 140&#x000a0;mg dosage group the minimum relative abundance was 13&#x000a0;% at 12&#x000a0;h (p&#x02009;=&#x02009;0.36). Graphed data are medians with median absolute deviations. <italic>APP</italic> amyloid precursor protein</p></caption><graphic xlink:href="13195_2016_178_Fig2_HTML" id="MO2"/></fig></p><p>Another peptide that changed in abundance was DELAPAGTGVSREAVSG (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>). The peptide is a fragment of amyloid-like protein 1 (APLP1), also known to be cleaved by &#x003b3;-secretase [<xref ref-type="bibr" rid="CR21">21</xref>]. The peptide, denoted APLP1&#x003b2;17, decreased by a maximum of 32&#x000a0;% after 12&#x000a0;h in the group that received 240&#x000a0;mg (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3b</xref>).<fig id="Fig3"><label>Fig. 3</label><caption><p>APL1&#x003b2;17. The peptide DELAPAGTGVSREAVSG, constituting fragment APL1&#x003b2;17 from amyloid-like protein 1 (APLP1). <bold>a</bold> Annotated MS2 spectrum. <bold>b</bold> Relative abundance of the peptide after semagacestat treatment. In the 280&#x000a0;mg dosage group the concentration of the peptide decreased to a minimum of 32&#x000a0;% at 12&#x000a0;h (p&#x02009;=&#x02009;0.0018), and in the 140&#x000a0;mg group the minimum relative concentration was 15&#x000a0;% at 18&#x000a0;h (p&#x02009;=&#x02009;0.078). Graphed data are medians with median absolute deviations</p></caption><graphic xlink:href="13195_2016_178_Fig3_HTML" id="MO3"/></fig></p><p>Of the remaining peptides, two were derived from proteins with transmembrane regions (Golgi apparatus protein 1 and CD99 antigen-like protein 2), which are thus potential gamma &#x003b3;-secretase substrates.</p></sec><sec id="Sec7" sec-type="discussion"><title>Discussion</title><p>While human CSF has been found to contain a large number of endogenous peptides, relatively little research has been performed to explore the potential of this class of molecules as a source of biomarkers. The current study is, to our knowledge, the first in which an explorative endopeptidomic approach has been employed to identify drug treatment biomarkers in CSF. Of 303 endogenous peptides that could be reproducibly identified in at least 50&#x000a0;% of the study participants, 11 differed significantly in abundance compared to t<sub>0</sub>, at one or several time points, and of these, two were derived from known gamma secretase substrates, which thus would be expected to be affected by the treatment. These proportions support our hypothesis that an unbiased peptidomic approach is sufficiently specific to detect treatment-induced changes on the peptide level.</p><p>While A&#x003b2;22-28, which decreased upon semagacestat treatment (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>), has not been previously identified in CSF, previous studies reported decreased levels of A&#x003b2;<sub>x-38</sub>, A&#x003b2;<sub>x-40</sub>, and A&#x003b2;<sub>x-42</sub> in CSF after a single dose [<xref ref-type="bibr" rid="CR19">19</xref>] and a decrease in the production of total A&#x003b2; in a dose dependent fashion [<xref ref-type="bibr" rid="CR9">9</xref>]. The &#x003b3;-secretase protease complex acts within the cellular membrane and cleaves its substrate proteins within their transmembrane-spanning region. Although position 28 in the A&#x003b2; sequence is at the edge of the transmembrane region (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4a</xref>), it has not been reported as a &#x003b3;-secretase cleavage site. Through mass spectrometry-based studies we have learned that several different A&#x003b2; peptides are present in the CSF and that they are affected differently by treatment [<xref ref-type="bibr" rid="CR22">22</xref>]. For example, we have previously shown, using immunoprecipitation in combination with MS, that chronic treatment of AD participants with semagacestat results in increased levels of A&#x003b2;1-15 and A&#x003b2;1-16 [<xref ref-type="bibr" rid="CR23">23</xref>]. Even though these short A&#x003b2; peptides are not generated directly by &#x003b3;-secretase cleavage, inhibition of &#x003b3;-secretase may induce an accumulation of C99, the transmembrane carboxyl-terminal domain of APP, which in turn is cleaved by &#x003b1;- and &#x003b2;-secretases resulting in increased levels of A&#x003b2;1-15 and A&#x003b2;1-16 [<xref ref-type="bibr" rid="CR24">24</xref>]. Thus, the observed decrease in A&#x003b2;22-28 does not necessarily imply that &#x003b3;-secretase cleaves at position 28 but may instead reflect decreased production of a longer A&#x003b2; peptide, which is then further cleaved by other proteases to A&#x003b2;22-28.<fig id="Fig4"><label>Fig. 4</label><caption><p>Transmembrane location of A&#x003b2;22-28 and APLP1&#x003b2;17. Location of the peptides (<bold>a</bold>) A&#x003b2;22-28 and (<bold>b</bold>) APLP1&#x003b2;17 relative to the transmembrane region of their respective protein sequences. The &#x003b3;-secretase cleavage sites in APP are indicated with <italic>arrows. APP</italic> amyloid precursor protein</p></caption><graphic xlink:href="13195_2016_178_Fig4_HTML" id="MO4"/></fig></p><p>That full-length A&#x003b2;40 or A&#x003b2;42 was not detected is a limitation of this study, resulting from steps in the sample preparation and analytical conditions: C<sub>18</sub> chromatographic media, used in LC-MS, may interact too strongly with the highly hydrophobic longer A&#x003b2; peptides, preventing their elution. Furthermore, following lyophilization, the samples were reconstituted in acidified aqueous solution, in which the solubility of the longer A&#x003b2; peptides is low. Using a complementary sample preparation, for example employing basic solvents, and C<sub>4</sub> or C<sub>8</sub> chromatographic media, may provide a more complete view on the processed peptides.</p><p>APL1&#x003b2;17, a 17-amino acid long peptide located near the transmembrane region of APLP1 (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4b</xref>), also decreased in response to the treatment (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>). The peptide showed a maximum decrease 12&#x000a0;h after drug intake, which matches observations of truncated A&#x003b2; peptides after treatment with semagacestat [<xref ref-type="bibr" rid="CR19">19</xref>]. Like APP, APLP1 also is a known substrate for &#x003b3;-secretase [<xref ref-type="bibr" rid="CR21">21</xref>]. It is processed around the transmembrane region by the same enzymes as APP, resulting in the formation of A&#x003b2;-like peptides [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]. Specifically, APLP1&#x003b2;25, APLP1&#x003b2;27, and APLP1&#x003b2;28 from APLP1 have been shown to be generated by &#x003b2; - and &#x003b3;-secretase cleavage [<xref ref-type="bibr" rid="CR25">25</xref>]. These peptides have, however, not been found to be a part of amyloid plaques [<xref ref-type="bibr" rid="CR25">25</xref>], in contrast to full length APLP1 [<xref ref-type="bibr" rid="CR26">26</xref>].</p><p>The overall levels of endogenous peptides increased over time in all groups; this has also been observed in a previous study of the same CSF samples [<xref ref-type="bibr" rid="CR19">19</xref>]. The increase may be caused by changes in the cephalic to caudal gradient when sampling CSF repeatedly over 36&#x000a0;hours. Therefore, in the current study, the increase was corrected for each endogenous peptide by subtracting the median value of the placebo group from the median value of the treatment groups.</p><p>The majority of the identified peptides that were affected by semagacestat treatment were not previously known &#x003b3;-secretase substrates. Notably, several of these were derived from proteins without transmembrane domains and would thus not be expected to be &#x003b3;-secretase substrates. This observation may indicate a direct or indirect modulation of protein metabolism through inhibition of &#x003b3;-secretase, suggesting that GSIs may have even broader biological effects than predicted from &#x003b3;-secretase substrates alone. The clinical trials with the drug failed because of a number of adverse effects, most importantly cognitive worsening, that occurred for unknown reasons. The changes observed in many of the endogenous peptides may not necessarily be the direct result of &#x003b3;-secretase activity, but may be caused by downstream &#x003b3;-secretase dependent processing or could be the result of drug effects on other proteases. These changes demonstrate the importance of analyzing the global composition of the samples in similar studies to elucidate whether a drug affects processes other than those expected or gives rise to unintended alterations among endogenous peptides or proteins. The information obtained in these experiments might also identify novel candidates for the enzymes whose functions are being modified with a treatment <italic>in vivo</italic>, which otherwise can be hard to identify/detect.</p></sec><sec id="Sec8" sec-type="conclusion"><title>Conclusions</title><p>Among the 303 endogenous peptides identified in total, a significant change in abundance in response to GSI treatment was detected in 11 peptides, and among those, two were derived from proteins that are known substrates to &#x003b3;-secretase. These results support our hypothesis that an unbiased endopeptidomic analytical approach can be used to detect peptides that are affected by drug treatment, and suggest that this approach may be valuable to include in future clinical trials.</p></sec></body><back><app-group><app id="App1"><sec id="Sec9"><title>Additional file</title><p><media position="anchor" xlink:href="13195_2016_178_MOESM1_ESM.xlsx" id="MOESM1"><label>Additional file 1: Table S1.</label><caption><p>Identified peptides. Peptides identified and quantified in at least four participants in each of the three treatment groups. Quantitative data are presented as percent change relative to CSF sampled at the time point when the drug was administered. The values are normalized to the average relative peptide abundance in the placebo group for each time point. (XLSX 86&#x000a0;kb)</p></caption></media></p></sec></app></app-group><glossary><title>Abbreviations</title><def-list><def-item><term>AD</term><def><p>Alzheimer&#x02019;s disease</p></def></def-item><def-item><term>APLP1</term><def><p>Amyloid-like protein 1</p></def></def-item><def-item><term>APP</term><def><p>Amyloid precursor protein</p></def></def-item><def-item><term>A&#x003b2;</term><def><p>beta-amyloid</p></def></def-item><def-item><term>CSF</term><def><p>Cerebrospinal fluid</p></def></def-item><def-item><term>GSI</term><def><p>&#x003b3;-secretase inhibitor</p></def></def-item><def-item><term>LC-MS</term><def><p>Liquid chromatography-mass spectrometry</p></def></def-item><def-item><term>TMT</term><def><p>Tandem mass tag</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Competing interests</bold></p><p>The authors declare that they have no competing interests.</p></fn><fn><p><bold>Authors&#x02019; contributions</bold></p><p>MH, JG, EP, and KB conceived the study. MH, JG, EP, KB, RAD, ES, KGM, WGS, PCM, DMH, and RJB organized the study and selected samples for analysis. MH and JG performed the analytical experiments, analyzed the data, and wrote the first draft. EP, KB, RAD, ES, KGM, WGS, PCM, DMH, and RJB reviewed the first draft and contributed to the manuscript. All authors read and approved the manuscript.</p></fn><fn><p><bold>Authors&#x02019; information</bold></p><p>MH performed the work as part of his Ph. D. project at the Clinical Neurochemistry Laboratory, M&#x000f6;lndal, where EP, HZ, KB, and JG are senior scientists. RAD and ES are senior Scientists at Lilly Research Laboratories. KGM, WGS, PCM, DMH, and RJB are senior scientists at the Department of Neurology, Washington University.</p></fn></fn-group><ack><title>Acknowledgements</title><p>This work was supported by the Swedish Research Council (521-2011-4709), the Knut and Alice Wallenberg Foundation, EMIF-AD, Emil och Wera Cornells stiftelse, Aina Wallstr&#x000f6;m och Mary-Ann Sj&#x000f6;bloms stiftelse, Demensf&#x000f6;rbundet, Magnus Bergvalls stiftelse, Adlerbertska stiftelsen, Stiftelsen f&#x000f6;r Gamla Tj&#x000e4;narinnor, Gun och Bertil Stohnes stiftelse, Kungl och Hvitfeldtska stiftelsen, Wilhelm och Martina Lundgrens vetenskapsfond, The Emil and Maria Palm Foundation, The Torsten S&#x000f6;derberg Foundation at the Royal Swedish Academy of Sciences, Stiftelsen Greta Johansson och Brita Anderssons minnesfond, Eli Lilly investigator initiated research grant (H6L-MC-LFAM, NIA K23 AG030946), The Knight Initiative for Alzheimer Research, NIH (CARS 1UL1 RR024992, NCRR 5P41 RR000954-32, NIDDK 2P60 DK020579-31, NIDDK SP30 DK056341-08). We gratefully acknowledge the research participants for their contributions.</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masters</surname><given-names>CL</given-names></name><name><surname>Simms</surname><given-names>G</given-names></name><name><surname>Weinman</surname><given-names>NA</given-names></name><name><surname>Multhaup</surname><given-names>G</given-names></name><name><surname>McDonald</surname><given-names>BL</given-names></name><name><surname>Beyreuther</surname><given-names>K</given-names></name></person-group><article-title>Amyloid plaque core protein in Alzheimer disease and Down syndrome</article-title><source>Proc Natl Acad Sci U S A.</source><year>1985</year><volume>82</volume><fpage>4245</fpage><lpage>4249</lpage><pub-id pub-id-type="doi">10.1073/pnas.82.12.4245</pub-id><pub-id pub-id-type="pmid">3159021</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masters</surname><given-names>CL</given-names></name><name><surname>Selkoe</surname><given-names>DJ</given-names></name></person-group><article-title>Biochemistry of amyloid beta-protein and amyloid deposits in Alzheimer disease</article-title><source>Cold Spring Harb Perspect Med.</source><year>2012</year><volume>2</volume><fpage>a006262</fpage><pub-id pub-id-type="doi">10.1101/cshperspect.a006262</pub-id><pub-id pub-id-type="pmid">22675658</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hardy</surname><given-names>J</given-names></name><name><surname>Selkoe</surname><given-names>DJ</given-names></name></person-group><article-title>The amyloid hypothesis of Alzheimer&#x02019;s disease: progress and problems on the road to therapeutics</article-title><source>Science.</source><year>2002</year><volume>297</volume><fpage>353</fpage><lpage>356</lpage><pub-id pub-id-type="doi">10.1126/science.1072994</pub-id><pub-id pub-id-type="pmid">12130773</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hardy</surname><given-names>JA</given-names></name><name><surname>Higgins</surname><given-names>GA</given-names></name></person-group><article-title>Alzheimer&#x02019;s disease: the amyloid cascade hypothesis</article-title><source>Science.</source><year>1992</year><volume>256</volume><fpage>184</fpage><lpage>185</lpage><pub-id pub-id-type="doi">10.1126/science.1566067</pub-id><pub-id pub-id-type="pmid">1566067</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blennow</surname><given-names>K</given-names></name><name><surname>Hampel</surname><given-names>H</given-names></name><name><surname>Zetterberg</surname><given-names>H</given-names></name></person-group><article-title>Biomarkers in amyloid-beta immunotherapy trials in Alzheimer&#x02019;s disease</article-title><source>Neuropsychopharmacology.</source><year>2014</year><volume>39</volume><fpage>189</fpage><lpage>201</lpage><pub-id pub-id-type="doi">10.1038/npp.2013.154</pub-id><pub-id pub-id-type="pmid">23799530</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mullane</surname><given-names>K</given-names></name><name><surname>Williams</surname><given-names>M</given-names></name></person-group><article-title>Alzheimer&#x02019;s therapeutics: continued clinical failures question the validity of the amyloid hypothesis-but what lies beyond?</article-title><source>Biochem Pharmacol.</source><year>2013</year><volume>85</volume><fpage>289</fpage><lpage>305</lpage><pub-id pub-id-type="doi">10.1016/j.bcp.2012.11.014</pub-id><pub-id pub-id-type="pmid">23178653</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andrieu</surname><given-names>S</given-names></name><name><surname>Coley</surname><given-names>N</given-names></name><name><surname>Lovestone</surname><given-names>S</given-names></name><name><surname>Aisen</surname><given-names>PS</given-names></name><name><surname>Vellas</surname><given-names>B</given-names></name></person-group><article-title>Prevention of sporadic Alzheimer&#x02019;s disease: lessons learned from clinical trials and future directions</article-title><source>Lancet Neurol.</source><year>2015</year><volume>14</volume><fpage>926</fpage><lpage>944</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(15)00153-2</pub-id><pub-id pub-id-type="pmid">26213339</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henley</surname><given-names>DB</given-names></name><name><surname>May</surname><given-names>PC</given-names></name><name><surname>Dean</surname><given-names>RA</given-names></name><name><surname>Siemers</surname><given-names>ER</given-names></name></person-group><article-title>Development of semagacestat (LY450139), a functional gamma-secretase inhibitor, for the treatment of Alzheimer&#x02019;s disease</article-title><source>Expert Opin Pharmacother.</source><year>2009</year><volume>10</volume><fpage>1657</fpage><lpage>1664</lpage><pub-id pub-id-type="doi">10.1517/14656560903044982</pub-id><pub-id pub-id-type="pmid">19527190</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bateman</surname><given-names>RJ</given-names></name><name><surname>Siemers</surname><given-names>ER</given-names></name><name><surname>Mawuenyega</surname><given-names>KG</given-names></name><name><surname>Wen</surname><given-names>G</given-names></name><name><surname>Browning</surname><given-names>KR</given-names></name><name><surname>Sigurdson</surname><given-names>WC</given-names></name><etal/></person-group><article-title>A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system</article-title><source>Ann Neurol.</source><year>2009</year><volume>66</volume><fpage>48</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1002/ana.21623</pub-id><pub-id pub-id-type="pmid">19360898</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doody</surname><given-names>RS</given-names></name><name><surname>Raman</surname><given-names>R</given-names></name><name><surname>Farlow</surname><given-names>M</given-names></name><name><surname>Iwatsubo</surname><given-names>T</given-names></name><name><surname>Vellas</surname><given-names>B</given-names></name><name><surname>Joffe</surname><given-names>S</given-names></name><name><surname>Kieburtz</surname><given-names>K</given-names></name><name><surname>He</surname><given-names>F</given-names></name><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>Thomas</surname><given-names>RG</given-names></name><name><surname>Aisen</surname><given-names>PS</given-names></name></person-group><article-title>Alzheimer&#x02019;s Disease Cooperative Study Steering Committee, Siemers E, Sethuraman G, Mohs R, Semagacestat Study Group. A phase 3 trial of semagacestat for treatment of Alzheimer&#x02019;s disease</article-title><source>N Engl J Med</source><year>2013</year><volume>369</volume><fpage>341</fpage><lpage>350</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1210951</pub-id><pub-id pub-id-type="pmid">23883379</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siemers</surname><given-names>ER</given-names></name><name><surname>Dean</surname><given-names>RA</given-names></name><name><surname>Friedrich</surname><given-names>S</given-names></name><name><surname>Ferguson-Sells</surname><given-names>L</given-names></name><name><surname>Gonzales</surname><given-names>C</given-names></name><name><surname>Farlow</surname><given-names>MR</given-names></name><etal/></person-group><article-title>Safety, tolerability, and effects on plasma and cerebrospinal fluid amyloid-beta after inhibition of gamma-secretase</article-title><source>Clin Neuropharmacol.</source><year>2007</year><volume>30</volume><fpage>317</fpage><lpage>325</lpage><pub-id pub-id-type="doi">10.1097/WNF.0b013e31805b7660</pub-id><pub-id pub-id-type="pmid">18090456</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holtta</surname><given-names>M</given-names></name><name><surname>Zetterberg</surname><given-names>H</given-names></name><name><surname>Mirgorodskaya</surname><given-names>E</given-names></name><name><surname>Mattsson</surname><given-names>N</given-names></name><name><surname>Blennow</surname><given-names>K</given-names></name><name><surname>Gobom</surname><given-names>J</given-names></name></person-group><article-title>Peptidome analysis of cerebrospinal fluid by LC-MALDI MS</article-title><source>PLoS One.</source><year>2012</year><volume>7</volume><fpage>e42555</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0042555</pub-id><pub-id pub-id-type="pmid">22880031</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jahn</surname><given-names>H</given-names></name><name><surname>Wittke</surname><given-names>S</given-names></name><name><surname>Zurbig</surname><given-names>P</given-names></name><name><surname>Raedler</surname><given-names>TJ</given-names></name><name><surname>Arlt</surname><given-names>S</given-names></name><name><surname>Kellmann</surname><given-names>M</given-names></name><etal/></person-group><article-title>Peptide fingerprinting of Alzheimer&#x02019;s disease in cerebrospinal fluid: identification and prospective evaluation of new synaptic biomarkers</article-title><source>PLoS One.</source><year>2011</year><volume>6</volume><fpage>e26540</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0026540</pub-id><pub-id pub-id-type="pmid">22046305</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stark</surname><given-names>M</given-names></name><name><surname>Danielsson</surname><given-names>O</given-names></name><name><surname>Griffiths</surname><given-names>WJ</given-names></name><name><surname>Jornvall</surname><given-names>H</given-names></name><name><surname>Johansson</surname><given-names>J</given-names></name></person-group><article-title>Peptide repertoire of human cerebrospinal fluid: novel proteolytic fragments of neuroendocrine proteins</article-title><source>J Chromatogr B Biomed Sci Appl.</source><year>2001</year><volume>754</volume><fpage>357</fpage><lpage>367</lpage><pub-id pub-id-type="doi">10.1016/S0378-4347(00)00628-9</pub-id><pub-id pub-id-type="pmid">11339279</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>X</given-names></name><name><surname>Desiderio</surname><given-names>DM</given-names></name></person-group><article-title>Human cerebrospinal fluid peptidomics</article-title><source>J Mass Spectrom.</source><year>2005</year><volume>40</volume><fpage>176</fpage><lpage>181</lpage><pub-id pub-id-type="doi">10.1002/jms.737</pub-id><pub-id pub-id-type="pmid">15706611</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zougman</surname><given-names>A</given-names></name><name><surname>Pilch</surname><given-names>B</given-names></name><name><surname>Podtelejnikov</surname><given-names>A</given-names></name><name><surname>Kiehntopf</surname><given-names>M</given-names></name><name><surname>Schnabel</surname><given-names>C</given-names></name><name><surname>Kumar</surname><given-names>C</given-names></name><etal/></person-group><article-title>Integrated analysis of the cerebrospinal fluid peptidome and proteome</article-title><source>J Proteome Res.</source><year>2008</year><volume>7</volume><fpage>386</fpage><lpage>399</lpage><pub-id pub-id-type="doi">10.1021/pr070501k</pub-id><pub-id pub-id-type="pmid">18052119</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dayon</surname><given-names>L</given-names></name><name><surname>Hainard</surname><given-names>A</given-names></name><name><surname>Licker</surname><given-names>V</given-names></name><name><surname>Turck</surname><given-names>N</given-names></name><name><surname>Kuhn</surname><given-names>K</given-names></name><name><surname>Hochstrasser</surname><given-names>DF</given-names></name><etal/></person-group><article-title>Relative quantification of proteins in human cerebrospinal fluids by MS/MS using 6-plex isobaric tags</article-title><source>Anal Chem.</source><year>2008</year><volume>80</volume><fpage>2921</fpage><lpage>2931</lpage><pub-id pub-id-type="doi">10.1021/ac702422x</pub-id><pub-id pub-id-type="pmid">18312001</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holtta</surname><given-names>M</given-names></name><name><surname>Minthon</surname><given-names>L</given-names></name><name><surname>Hansson</surname><given-names>O</given-names></name><name><surname>Holmen-Larsson</surname><given-names>J</given-names></name><name><surname>Pike</surname><given-names>I</given-names></name><name><surname>Ward</surname><given-names>M</given-names></name><etal/></person-group><article-title>An integrated workflow for multiplex CSF proteomics and peptidomics-identification of candidate cerebrospinal fluid biomarkers of Alzheimer&#x02019;s disease</article-title><source>J Proteome Res.</source><year>2015</year><volume>14</volume><fpage>654</fpage><lpage>663</lpage><pub-id pub-id-type="doi">10.1021/pr501076j</pub-id><pub-id pub-id-type="pmid">25490617</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Portelius</surname><given-names>E</given-names></name><name><surname>Zetterberg</surname><given-names>H</given-names></name><name><surname>Dean</surname><given-names>RA</given-names></name><name><surname>Marcil</surname><given-names>A</given-names></name><name><surname>Bourgeois</surname><given-names>P</given-names></name><name><surname>Nutu</surname><given-names>M</given-names></name><etal/></person-group><article-title>Amyloid-beta(1-15/16) as a marker for gamma-secretase inhibition in Alzheimer&#x02019;s disease</article-title><source>J Alzheimers Dis.</source><year>2012</year><volume>31</volume><fpage>335</fpage><lpage>341</lpage><pub-id pub-id-type="pmid">22531418</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vizcaino</surname><given-names>JA</given-names></name><name><surname>Deutsch</surname><given-names>EW</given-names></name><name><surname>Wang</surname><given-names>R</given-names></name><name><surname>Csordas</surname><given-names>A</given-names></name><name><surname>Reisinger</surname><given-names>F</given-names></name><name><surname>Rios</surname><given-names>D</given-names></name><etal/></person-group><article-title>ProteomeXchange provides globally coordinated proteomics data submission and dissemination</article-title><source>Nat Biotechnol.</source><year>2014</year><volume>32</volume><fpage>223</fpage><lpage>226</lpage><pub-id pub-id-type="doi">10.1038/nbt.2839</pub-id><pub-id pub-id-type="pmid">24727771</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eggert</surname><given-names>S</given-names></name><name><surname>Paliga</surname><given-names>K</given-names></name><name><surname>Soba</surname><given-names>P</given-names></name><name><surname>Evin</surname><given-names>G</given-names></name><name><surname>Masters</surname><given-names>CL</given-names></name><name><surname>Weidemann</surname><given-names>A</given-names></name><etal/></person-group><article-title>The proteolytic processing of the amyloid precursor protein gene family members APLP-1 and APLP-2 involves alpha-, beta-, gamma-, and epsilon-like cleavages: modulation of APLP-1 processing by n-glycosylation</article-title><source>J Biol Chem.</source><year>2004</year><volume>279</volume><fpage>18146</fpage><lpage>18156</lpage><pub-id pub-id-type="doi">10.1074/jbc.M311601200</pub-id><pub-id pub-id-type="pmid">14970212</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Portelius</surname><given-names>E</given-names></name><name><surname>Mattsson</surname><given-names>N</given-names></name><name><surname>Andreasson</surname><given-names>U</given-names></name><name><surname>Blennow</surname><given-names>K</given-names></name><name><surname>Zetterberg</surname><given-names>H</given-names></name></person-group><article-title>Novel abeta isoforms in Alzheimer&#x02019;s disease - their role in diagnosis and treatment</article-title><source>Curr Pharm Des.</source><year>2011</year><volume>17</volume><fpage>2594</fpage><lpage>2602</lpage><pub-id pub-id-type="doi">10.2174/138161211797416039</pub-id><pub-id pub-id-type="pmid">21728980</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Portelius</surname><given-names>E</given-names></name><name><surname>Dean</surname><given-names>RA</given-names></name><name><surname>Gustavsson</surname><given-names>MK</given-names></name><name><surname>Andreasson</surname><given-names>U</given-names></name><name><surname>Zetterberg</surname><given-names>H</given-names></name><name><surname>Siemers</surname><given-names>E</given-names></name><etal/></person-group><article-title>A novel Abeta isoform pattern in CSF reflects gamma-secretase inhibition in Alzheimer disease</article-title><source>Alzheimers Res Ther.</source><year>2010</year><volume>2</volume><fpage>7</fpage><pub-id pub-id-type="doi">10.1186/alzrt30</pub-id><pub-id pub-id-type="pmid">20350302</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Portelius</surname><given-names>E</given-names></name><name><surname>Price</surname><given-names>E</given-names></name><name><surname>Brinkmalm</surname><given-names>G</given-names></name><name><surname>Stiteler</surname><given-names>M</given-names></name><name><surname>Olsson</surname><given-names>M</given-names></name><name><surname>Persson</surname><given-names>R</given-names></name><etal/></person-group><article-title>A novel pathway for amyloid precursor protein processing</article-title><source>Neurobiol Aging.</source><year>2011</year><volume>32</volume><fpage>1090</fpage><lpage>1098</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2009.06.002</pub-id><pub-id pub-id-type="pmid">19604603</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yanagida</surname><given-names>K</given-names></name><name><surname>Okochi</surname><given-names>M</given-names></name><name><surname>Tagami</surname><given-names>S</given-names></name><name><surname>Nakayama</surname><given-names>T</given-names></name><name><surname>Kodama</surname><given-names>TS</given-names></name><name><surname>Nishitomi</surname><given-names>K</given-names></name><etal/></person-group><article-title>The 28-amino acid form of an APLP1-derived Abeta-like peptide is a surrogate marker for Abeta42 production in the central nervous system</article-title><source>EMBO Mol Med.</source><year>2009</year><volume>1</volume><fpage>223</fpage><lpage>235</lpage><pub-id pub-id-type="doi">10.1002/emmm.200900026</pub-id><pub-id pub-id-type="pmid">20049724</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bayer</surname><given-names>TA</given-names></name><name><surname>Paliga</surname><given-names>K</given-names></name><name><surname>Weggen</surname><given-names>S</given-names></name><name><surname>Wiestler</surname><given-names>OD</given-names></name><name><surname>Beyreuther</surname><given-names>K</given-names></name><name><surname>Multhaup</surname><given-names>G</given-names></name></person-group><article-title>Amyloid precursor-like protein 1 accumulates in neuritic plaques in Alzheimer&#x02019;s disease</article-title><source>Acta Neuropathol.</source><year>1997</year><volume>94</volume><fpage>519</fpage><lpage>524</lpage><pub-id pub-id-type="doi">10.1007/s004010050745</pub-id><pub-id pub-id-type="pmid">9444352</pub-id></element-citation></ref></ref-list></back></article>